Self-sampling samples will be subjected to HPV genotyping. In parallel, high-risk HPV positive women will be called in by their family doctors to undergo screening in a clinical setting so that they can continue their clinical follow-up in the conventional pathway. conditions: Papillomavirus Infections conditions: Early Detection of Cancer conditions: Cervix Cancer conditions: Self-Examination studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 1000 type: ESTIMATED name: Directly mailed self-sampling kit to collect a vaginal sample name: Mailed self-sampling kit to collect a vaginal sample after opt-in prodecure name: Standard of care - screening in a clinical setting measure: Adherence to conventional screening in control group measure: Adherence to HPV self-sampling in intervention 1 (directly mailed) group measure: Adherence to HPV self-sampling in intervention 2 (opt-in) group measure: Adherence proportion to HPV self-sampling in intervention 1 (directly mailed) group VS Adherence proportion to conventional screening in control group measure: Adherence proportion to HPV self-sampling in intervention 2 (opt-in) group VS Adherence proportion to conventional screening in control group measure: Adherence to first follow-up step in control group measure: Adherence to first follow-up step in intervention 1 (directly mailed) group measure: Adherence to first follow-up step in intervention 2 (opt-in) group measure: Adherence to first follow-up step in control group among women referred for follow-up measure: Adherence to first follow-up step in intervention 1 (directly mailed) group among women referred for folow-up measure: Adherence to first follow-up step in intervention 2 (opt-in) group among women referred for folow-up measure: Adherence to colposcopy in control group measure: Adherence to colposcopy in intervention 1 (directly mailed) group measure: Adherence to colposcopy in intervention 2 (opt-in) group measure: Adherence to colposcopy in control group among women referred for colposcopy measure: Adherence to colposcopy in intervention 1 (directly mailed) group among women referred for colposcopy measure: Adherence to colposcopy in intervention 2 (opn-in) group among women referred for colposcopy measure: Timelapse (in days) between the shipment of self-sampling kit and the return of the sample, in intervention 1 (directly mailed) group measure: Timelapse (in days) between the invitation to receive a self-sampling kit and the return of the opt-in answer, in intervention 2 (opt-in) group measure: Timelapse (in days) between the shipment of self-sampling kit and the return of the sample, in intervention 2 (opt-in) group measure: Adherence proportion to first follow-up step in intervention 1 (directly mailed) group VS Adherence proportion to first follow-up step in control group measure: Adherence proportion to first follow-up step in intervention 2 (opt-in) group VS Adherence proportion to first follow-up step in control group measure: Adherence proportion to first follow-up step in intervention 1 (directly mailed) group among women referred for follow-up VS Adherence proportion to first follow-up step in control group among women referred for follow-up measure: Adherence proportion to first follow-up step in intervention 2 (opt-in) group among women referred for follow-up VS Adherence proportion to first follow-up step in control group among women referred for follow-up measure: Adherence proportion to colposcopy in intervention 1 (directly mailed) group VS Adherence proportion to colposcopy in control group measure: Adherence proportion to colposcopy in intervention 2 (opt-in) group VS Adherence proportion to colposcopy in control group measure: Adherence proportion to colposcopy in intervention 1 (directly mailed) group among women referred for colposcopy VS Adherence proportion to colposcopy in control group among women referred for colposcopy measure: Adherence proportion to colposcopy in intervention 2 (opt-in) group among women referred for colposcopy VS Adherence proportion to colposcopy in control group among women referred for colposcopy measure: Proportion of HR-HPV positivity in control group measure: Proportion of HR-HPV positivity in intervention 1 (directly mailed) group measure: Proportion of HR-HPV positivity in intervention 2 (opt-in) group measure: Proportion of HR-HPV positivity in control group among women who adhered to conventional screening measure: Proportion of HR-HPV positivity in intervention 1 (directly mailed) group among women who returned the self-sample measure: Proportion of HR-HPV positivity in intervention 2 (opt-in) group among women who returned the self-sample measure: Proportion of HR-HPV 16/18 positivity in control group measure: Proportion of HR-HPV 16/18 positivity in intervention 1 (directly mailed) group measure: Proportion of HR-HPV 16/18 positivity in intervention 2 (opt-in) group measure: Proportion of HR-HPV 16/18 positivity in control group among women who adhered to conventional screening measure: Proportion of HR-HPV 16/18 positivity in intervention 1 (directly mailed) group among women who returned the self-sample measure: Proportion of HR-HPV 16/18 positivity in intervention 2 (opt-in) group among women who returned the self-sample measure: Positive predictive value of self-sampling for the detection of HR-HPV, using clinician-sampling results as gold standard measure: Sensitivity of HR-HPV testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Specificity of HR-HPV testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Positive likelihood ratio of HR-HPV testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Negative likelihood ratio of HR-HPV testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Accuracy of HR-HPV testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Sensitivity of HR-HPV non 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Specificity of HR-HPV non 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Positive likelihood ratio of HR-HPV non 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Negative likelihood ratio of HR-HPV non 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Accuracy of HR-HPV non 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Sensitivity of HR-HPV 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Specificity of HR-HPV 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Positive likelihood ratio of HR-HPV 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Negative likelihood ratio of HR-HPV 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard measure: Accuracy of HR-HPV 16/18 testing and methylation analysis in self-samples, using biopsy results as gold standard sex: FEMALE minimumAge: 26 Years maximumAge: 60 Years stdAges: ADULT hasResults: False